Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 1,590 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total transaction of $48,463.20. Following the sale, the insider now owns 251,033 shares of the company's stock, valued at $7,651,485.84. This represents a 0.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Carl Dambkowski also recently made the following trade(s):
Apogee Therapeutics stock traded up $0.70 during trading hours on Friday, reaching $36.14. 1,271,963 shares of the stock were exchanged, compared to its average volume of 590,358. The stock has a market cap of $1.63 billion, a P/E ratio of -14.93 and a beta of 2.46. Apogee Therapeutics, Inc. has a 52-week low of $29.10 and a 52-week high of $72.29. The firm's 50 day moving average is $39.12 and its 200 day moving average is $47.02.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). Equities research analysts expect that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.
Several analysts recently commented on APGE shares. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price target for the company. Wedbush reiterated an "outperform" rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a "buy" rating and a $89.00 price objective for the company. Finally, Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $91.60.
Check Out Our Latest Analysis on Apogee Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Apogee Therapeutics during the 4th quarter worth approximately $43,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Apogee Therapeutics in the 3rd quarter valued at approximately $71,000. Optimize Financial Inc acquired a new position in Apogee Therapeutics during the fourth quarter worth $203,000. Aigen Investment Management LP acquired a new position in Apogee Therapeutics during the fourth quarter worth $216,000. Finally, BNP Paribas Financial Markets acquired a new position in Apogee Therapeutics during the fourth quarter worth $219,000. 79.04% of the stock is owned by hedge funds and other institutional investors.
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.